The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic ('intrinsic') asthma: a double-blind, randomised, placebo-controlled trial

Trial Profile

The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic ('intrinsic') asthma: a double-blind, randomised, placebo-controlled trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms XONAA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Aug 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 16 Mar 2012 Actual initiation date changed from Apr 2010 to Jul 2009 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top